Emerging evidence suggests that not all KRAS‐driven tumours are biologically equivalent; subtype‐specific features—such as co‐occurring mutations, metabolic reprogramming and immune‐suppressive stromal interactions—play critical roles in shaping therapeutic vulnerabilities and resistance mechanisms.15, 16. This evidence concerns the gene KRAS and neoplasm.